Evidence map›Paper›PMID 24553735›Full record

ArticleMarine biotechnology (New York, N.Y.)2014

Metabolism and resistance of Fusarium spp. to the manzamine alkaloids via a putative retro pictet-spengler reaction and utility of the rational design of antimalarial and antifungal agents.

Noer Kasanah, Lorelei Lucas Farr, Abbas Gholipour, David E Wedge, Mark T Hamann

Abstract read
In one paragraph

Article in Marine biotechnology (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Pictet-Spengler Reaction Updates Its Habits.Molecules (Basel, Switzerland) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Noer KasanahDepartment of Pharmacognosy, School of Pharmacy, The University of Mississippi, Oxford, MS, USA, noer.kasanah@gmail.com.
Lorelei Lucas Farr
Abbas Gholipour
David E Wedge
Mark T Hamann

Funding

ANTIAIDS AGENTS FROM MARINE ORGANISMSR01AI036596 · NIAID · UNIVERSITY OF MISSISSIPPI · PI HAMANN, MARK T · 2001 to 2007
$2.3M
Natural Product HCV Drugs from Rare Plant-Microbe InteractionsR01AT007318 · NCCIH · UNIVERSITY OF MISSISSIPPI · PI HAMANN, MARK T · 2012 to 2016
$1.6M
NCCIH NIH HHS R01 AT007318NIAID NIH HHS R01 AI036596
6 · The paper itself

Abstract

As a part of our continuing investigation of the manzamine alkaloids we studied the in vitro activity of the β-carboline containing manzamine alkaloids against Fusarium solani, Fusarium oxysporium, and Fusarium proliferatum by employing several bioassay techniques including one-dimensional direct bioautography, dilution, and plate susceptibility, and microtiter broth assays. In addition, we also studied the metabolism of the manzamine alkaloids by Fusarium spp. in order to facilitate the redesign of the compounds to prevent resistance of Fusarium spp. through metabolism. The present research reveals that the manzamine alkaloids are inactive against Fusarium spp. and the fungi transform manzamines via hydrolysis, reduction, and a retro Pictet-Spengler reaction. This is the first report to demonstrate an enzymatically retro Pictet-Spengler reaction. The results of this study reveal the utility of the rational design of metabolically stable antifungal agents from this class and the development of manzamine alkaloids as antimalarial drugs through the utilization of Fusarium's metabolic products to reconstruct the molecule.

Indexed as

AlkaloidsAntifungal AgentsAntimalarialsCarbazolesCell SurvivalDose-Response Relationship, DrugDrug DesignDrug Resistance, FungalFusariumSpecies SpecificityAlkaloidsAntifungal AgentsAntimalarialsCarbazoles

Identifiers

PMID24553735
PMCPMC4139108

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.